Evidence map›Paper›PMID 26067326›Full record

ArticleScientific reports2015

Serum Exosome MicroRNA as a Minimally-Invasive Early Biomarker of AML.

Noah I Hornick, Jianya Huan, Ben Doron, Natalya A Goloviznina, Jodi Lapidus, Bill H Chang, Peter Kurre

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed, 2 pooled it
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

163 citing papers in PubMed, 2 syntheses or guidelines pooled it, 248 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Exosome-like Nanovesicles fromMolecules (Basel, Switzerland) · 2026
    Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

103 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Noah I Hornick1] Department of Pediatrics, Oregon Health &Science University, Portland, OR [2] Department of Medicine, Oregon Health &Science University, Portland, OR [3] Papé Family Pediatric Research Institute, Oregon Health &Science University, Portland, OR.
Jianya Huan1] Department of Pediatrics, Oregon Health &Science University, Portland, OR [2] Department of Medicine, Oregon Health &Science University, Portland, OR [3] Papé Family Pediatric Research Institute, Oregon Health &Science University, Portland, OR.
Ben Doron1] Department of Pediatrics, Oregon Health &Science University, Portland, OR [2] Department of Medicine, Oregon Health &Science University, Portland, OR [3] Papé Family Pediatric Research Institute, Oregon Health &Science University, Portland, OR.
Natalya A Goloviznina1] Department of Pediatrics, Oregon Health &Science University, Portland, OR [2] Department of Medicine, Oregon Health &Science University, Portland, OR [3] Papé Family Pediatric Research Institute, Oregon Health &Science University, Portland, OR.
Jodi LapidusDepartment of Public Health, Oregon Health &Science University, Portland, OR.
Bill H Chang1] Department of Pediatrics, Oregon Health &Science University, Portland, OR [2] Department of Medicine, Oregon Health &Science University, Portland, OR [3] Papé Family Pediatric Research Institute, Oregon Health &Science University, Portland, OR [4] Knight Cancer Institute, Oregon Health &Science University, Portland, OR.
Peter Kurre1] Department of Pediatrics, Oregon Health &Science University, Portland, OR [2] Department of Medicine, Oregon Health &Science University, Portland, OR [3] Papé Family Pediatric Research Institute, Oregon Health &Science University, Portland, OR [4] Knight Cancer Institute, Oregon Health &Science University, Portland, OR.
Oregon Health & Science University · US

Funding

Oregon Clinical and Translational Research InstituteUL1TR000128 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLISON, DAVID H · 2012 to 2015
$28.7M
Exosomal MicroRNA as a Driver of Immune Evasion in AMLF30CA183269 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI HORNICK, NOAH IO · 2014 to 2016
$139k
NCATS NIH HHS UL1 TR000128NCI NIH HHS 1F30CA183269-01NCI NIH HHS F30 CA183269
6 · The paper itself

Abstract

Relapse remains the major cause of mortality for patients with Acute Myeloid Leukemia (AML). Improved tracking of minimal residual disease (MRD) holds the promise of timely treatment adjustments to preempt relapse. Current surveillance techniques detect circulating blasts that coincide with advanced disease and poorly reflect MRD during early relapse. Here, we investigate exosomes as a minimally invasive platform for a microRNA (miRNA) biomarker. We identify a set of miRNA enriched in AML exosomes and track levels of circulating exosome miRNA that distinguish leukemic xenografts from both non-engrafted and human CD34+ controls. We develop biostatistical models that reveal circulating exosomal miRNA at low marrow tumor burden and before circulating blasts can be detected. Remarkably, both leukemic blasts and marrow stroma contribute to serum exosome miRNA. We propose development of serum exosome miRNA as a platform for a novel, sensitive compartment biomarker for prospective tracking and early detection of AML recurrence.

Indexed as

AnimalsBiomarkers, TumorExosomesHL-60 CellsHumansLeukemia, Myeloid, AcuteMiceMice, Inbred NODMice, SCIDMicroRNAsNeoplasms, ExperimentalRNA, NeoplasmU937 CellsBiomarkers, TumorMicroRNAsRNA, Neoplasm

Identifiers

PMID26067326
PMCPMC4650871
OpenAlexW2256328335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.